Kiora Other Current Liab from 2010 to 2024

KPRX Stock  USD 3.32  0.05  1.48%   
Kiora Pharmaceuticals Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities will likely drop to about 1.3 M in 2024. During the period from 2010 to 2024, Kiora Pharmaceuticals Other Current Liabilities regression line of annual values had r-squared of  0.47 and arithmetic mean of  1,107,335. View All Fundamentals
 
Other Current Liabilities  
First Reported
2013-12-31
Previous Quarter
1.2 M
Current Value
2.7 M
Quarterly Volatility
580.6 K
 
Yuan Drop
 
Covid
Check Kiora Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiora Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.2 K, Selling General Administrative of 4.8 M or Other Operating Expenses of 10.3 M, as well as many indicators such as Price To Sales Ratio of 16 K, Dividend Yield of 0.0 or PTB Ratio of 0.43. Kiora financial statements analysis is a perfect complement when working with Kiora Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kiora Pharmaceuticals Correlation against competitors.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Latest Kiora Pharmaceuticals' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Kiora Pharmaceuticals over the last few years. It is Kiora Pharmaceuticals' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Kiora Other Current Liab Regression Statistics

Arithmetic Mean1,107,335
Geometric Mean984,760
Coefficient Of Variation45.49
Mean Deviation387,404
Median1,120,480
Standard Deviation503,767
Sample Variance253.8B
Range1.7M
R-Value0.69
Mean Square Error144.6B
R-Squared0.47
Significance0
Slope77,307
Total Sum of Squares3.6T

Kiora Other Current Liab History

20241.3 M
20231.3 M
20222.1 M
20211.2 M
20201.3 M
20191.1 M
20181.1 M

About Kiora Pharmaceuticals Financial Statements

Kiora Pharmaceuticals investors use historical fundamental indicators, such as Kiora Pharmaceuticals' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kiora Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities1.3 M1.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.